CST3 and stage 5 chronic kidney disease: Recently, CKD outcome studies have established that cystatin C and albuminuria can improve risk stratification among persons with CKD defined by eGFRcr, with respect to mortality risk, cardiovascular disease, heart failure, and end stage renal disease [22, 42–44].